Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2018 3
2019 2
2020 1
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for imatinib bioorganic
Your search for imatynib-bioorganics retrieved no results
Modular synthesis of new C-aryl-nucleosides and their anti-CML activity.
Marzag H, Zerhouni M, Tachallait H, Demange L, Robert G, Bougrin K, Auberger P, Benhida R. Marzag H, et al. Bioorg Med Chem Lett. 2018 Jun 1;28(10):1931-1936. doi: 10.1016/j.bmcl.2018.03.063. Epub 2018 Mar 24. Bioorg Med Chem Lett. 2018. PMID: 29655981
Among them, we observed that 5d exerts promising anti-proliferative effects against two human Chronic Myeloid Leukemia (CML) cell lines, both sensitive (K562-S) or resistant (K562-R) to imatinib, the "gold standard of care" used in this pathology. Moreover, we demonstrated …
Among them, we observed that 5d exerts promising anti-proliferative effects against two human Chronic Myeloid Leukemia (CML) cell lines, bot …
Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells.
Çiftçi H. Çiftçi H. Turk J Pharm Sci. 2020 Feb;17(1):49-55. doi: 10.4274/tjps.galenos.2018.49389. Epub 2020 Feb 19. Turk J Pharm Sci. 2020. PMID: 32454760 Free PMC article.
OBJECTIVES: Chronic myelogenous leukemia (CML) is a type of blood cancer that is initially treated with imatinib (first Abl kinase inhibitor). However, some patients with CML develop imatinib resistance. ...MATERIALS AND METHODS: The MTT cell proliferation assay was …
OBJECTIVES: Chronic myelogenous leukemia (CML) is a type of blood cancer that is initially treated with imatinib (first Abl kinase in …
Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes.
Lebedev T, Vagapova E, Spirin P, Rubtsov P, Astashkova O, Mikheeva A, Sorokin M, Vladimirova U, Suntsova M, Konovalov D, Roumiantsev A, Stocking C, Buzdin A, Prassolov V. Lebedev T, et al. Oncogene. 2021 Nov;40(44):6258-6272. doi: 10.1038/s41388-021-02018-7. Epub 2021 Sep 23. Oncogene. 2021. PMID: 34556815 Free PMC article.
In a therapeutic setting, we showed that among six selected growth factors, EPO, and NGF showed the most pronounced protective effects in vitro against several promising anti-NB multikinase inhibitors: imatinib, dasatinib, crizotinib, cabozantinib, and axitinib. Mechanisti …
In a therapeutic setting, we showed that among six selected growth factors, EPO, and NGF showed the most pronounced protective effects in vi …
The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Ciftci HI, Ozturk SE, Ali TFS, Radwan MO, Tateishi H, Koga R, Ocak Z, Can M, Otsuka M, Fujita M. Ciftci HI, et al. Biol Pharm Bull. 2018 Apr 1;41(4):570-574. doi: 10.1248/bpb.b17-00902. Epub 2018 Jan 30. Biol Pharm Bull. 2018. PMID: 29386476 Free article.
However, some CML patients show drug resistance to imatinib. To address this issue, some artificial heterocyclic compounds have been identified as BCR-ABL inhibitors. ...In addition, compound 1c showed a different inhibitory profile against eight kinases compared with i …
However, some CML patients show drug resistance to imatinib. To address this issue, some artificial heterocyclic compounds have been …
[Coupling capillary electrophoresis-electrospray ionization mass spectrometry with sheathless interface for drug analysis].
Zhang H, Li F, Kang J. Zhang H, et al. Se Pu. 2023 Feb;41(2):160-167. doi: 10.3724/SP.J.1123.2022.07015. Se Pu. 2023. PMID: 36725712 Free PMC article. Chinese.
In the present work, we explored the application of the sheathless CE-MS interface which was prepared by gold foil-wrapped CE separation column tip directly as a spray electrode for the analysis of five tyrosine kinase inhibitors, namely sunitinib, imatinib mesylate …
In the present work, we explored the application of the sheathless CE-MS interface which was prepared by gold foil-wrapped CE separation col …
In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase.
Koroleva EV, Kornoushenko YV, Karpenko AD, Bosko IP, Siniutsich JV, Ignatovich ZV, Andrianov AM. Koroleva EV, et al. J Biomol Struct Dyn. 2023 Jun;41(9):4065-4080. doi: 10.1080/07391102.2022.2062784. Epub 2022 Apr 26. J Biomol Struct Dyn. 2023. PMID: 35470777
This approach included i) design of chimeric molecules based on the 2-arylaminopyrimidine fragment, the main pharmacophore of the Abl kinase inhibitors imatinib and nilotinib used in the clinic for the CML treatment, ii) molecular docking of these compounds with the ATP-bi …
This approach included i) design of chimeric molecules based on the 2-arylaminopyrimidine fragment, the main pharmacophore of the Abl kinase …
Design, synthesis, and biological activity of Plastoquinone analogs as a new class of anticancer agents.
Bayrak N, Yıldırım H, Yıldız M, Radwan MO, Otsuka M, Fujita M, Tuyun AF, Ciftci HI. Bayrak N, et al. Bioorg Chem. 2019 Nov;92:103255. doi: 10.1016/j.bioorg.2019.103255. Epub 2019 Sep 7. Bioorg Chem. 2019. PMID: 31542717
PQ2 showed anti-Abelson kinase 1 (Abl1) activity with different inhibitory profile than Imatinib in the panel of eight kinases. The binding mode of PQ2 into Abl ATP binding pocket was predicted in silico showing the formation of some key interactions. ...
PQ2 showed anti-Abelson kinase 1 (Abl1) activity with different inhibitory profile than Imatinib in the panel of eight kinases. The b …
A method of gene expression data transfer from cell lines to cancer patients for machine-learning prediction of drug efficiency.
Borisov N, Tkachev V, Suntsova M, Kovalchuk O, Zhavoronkov A, Muchnik I, Buzdin A. Borisov N, et al. Cell Cycle. 2018;17(4):486-491. doi: 10.1080/15384101.2017.1417706. Epub 2018 Jan 17. Cell Cycle. 2018. PMID: 29251172 Free PMC article.
The method was validated on three datasets for cancer-like diseases (chronic myeloid leukemia, as well as lung adenocarcinoma and renal carcinoma) treated with targeted drugs - kinase inhibitors, such as imatinib or sorafenib....
The method was validated on three datasets for cancer-like diseases (chronic myeloid leukemia, as well as lung adenocarcinoma and renal carc …
PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.
Velghe AI, Van Cauwenberghe S, Polyansky AA, Chand D, Montano-Almendras CP, Charni S, Hallberg B, Essaghir A, Demoulin JB. Velghe AI, et al. Oncogene. 2014 May 15;33(20):2568-76. doi: 10.1038/onc.2013.218. Epub 2013 Jun 10. Oncogene. 2014. PMID: 23752188
Activating mutations in the platelet-derived growth factor (PDGF) receptor alpha (PDGFRA) have been described in patients with gastrointestinal stromal tumors or myeloid malignancies associated with hypereosinophilia. These patients respond well to imatinib mesylate …
Activating mutations in the platelet-derived growth factor (PDGF) receptor alpha (PDGFRA) have been described in patients with gastrointesti …
11 results